Cargando…

Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad

Most of the complications and deaths related to seasonal flu occur in the elderly population (≥65 years) with comorbidities, and the influenza vaccine is the most effective way to prevent them. Immunization is less effective in older adults due to immunosenescence. MF59-adjuvanted vaccines, designed...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez, María Pilar Arrazola, Bouza, José María Eiros, Rubió, Pere Plans, Puig-Barberà, Joan, Aragón, Jesús Ruiz, Lana, Álvaro Torres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336316/
https://www.ncbi.nlm.nih.gov/pubmed/37079707
http://dx.doi.org/10.37201/req/145.2022
_version_ 1785071184422895616
author Martínez, María Pilar Arrazola
Bouza, José María Eiros
Rubió, Pere Plans
Puig-Barberà, Joan
Aragón, Jesús Ruiz
Lana, Álvaro Torres
author_facet Martínez, María Pilar Arrazola
Bouza, José María Eiros
Rubió, Pere Plans
Puig-Barberà, Joan
Aragón, Jesús Ruiz
Lana, Álvaro Torres
author_sort Martínez, María Pilar Arrazola
collection PubMed
description Most of the complications and deaths related to seasonal flu occur in the elderly population (≥65 years) with comorbidities, and the influenza vaccine is the most effective way to prevent them. Immunization is less effective in older adults due to immunosenescence. MF59-adjuvanted vaccines, designed to improve the magnitude, persistence and amplitude of the immune response in elderly people, have been used in clinical practice since 1997 in their trivalent formulation and, since 2020, in their tetravalent formulation. Data from various studies show that these vaccines are not only safe for all age groups, with a reactogenicity profile similar to that of the conventional vaccine, but also that they are especially effective in boosting the immune response in the population aged 65 or over by increasing antibody titers after vaccination and significantly reducing the risk of hospital admission. Adjuvanted vaccines have been shown to provide cross-protection against heterologous strains and to be as effective as the high-dose vaccine in the population aged 65 or over. In this review, the scientific evidence on the efficacy and effectiveness of the MF59-adjuvanted vaccine in real clinical practice in people ≥65 years of age is analyzed through a narrative and descriptive review of the literature with data from clinical trials, observational studies and systematic reviews or meta-analysis.
format Online
Article
Text
id pubmed-10336316
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-103363162023-07-13 Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad Martínez, María Pilar Arrazola Bouza, José María Eiros Rubió, Pere Plans Puig-Barberà, Joan Aragón, Jesús Ruiz Lana, Álvaro Torres Rev Esp Quimioter Review Most of the complications and deaths related to seasonal flu occur in the elderly population (≥65 years) with comorbidities, and the influenza vaccine is the most effective way to prevent them. Immunization is less effective in older adults due to immunosenescence. MF59-adjuvanted vaccines, designed to improve the magnitude, persistence and amplitude of the immune response in elderly people, have been used in clinical practice since 1997 in their trivalent formulation and, since 2020, in their tetravalent formulation. Data from various studies show that these vaccines are not only safe for all age groups, with a reactogenicity profile similar to that of the conventional vaccine, but also that they are especially effective in boosting the immune response in the population aged 65 or over by increasing antibody titers after vaccination and significantly reducing the risk of hospital admission. Adjuvanted vaccines have been shown to provide cross-protection against heterologous strains and to be as effective as the high-dose vaccine in the population aged 65 or over. In this review, the scientific evidence on the efficacy and effectiveness of the MF59-adjuvanted vaccine in real clinical practice in people ≥65 years of age is analyzed through a narrative and descriptive review of the literature with data from clinical trials, observational studies and systematic reviews or meta-analysis. Sociedad Española de Quimioterapia 2023-04-20 2023 /pmc/articles/PMC10336316/ /pubmed/37079707 http://dx.doi.org/10.37201/req/145.2022 Text en © The Author 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Review
Martínez, María Pilar Arrazola
Bouza, José María Eiros
Rubió, Pere Plans
Puig-Barberà, Joan
Aragón, Jesús Ruiz
Lana, Álvaro Torres
Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad
title Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad
title_full Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad
title_fullStr Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad
title_full_unstemmed Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad
title_short Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad
title_sort eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336316/
https://www.ncbi.nlm.nih.gov/pubmed/37079707
http://dx.doi.org/10.37201/req/145.2022
work_keys_str_mv AT martinezmariapilararrazola eficaciaefectividadyseguridaddelavacunaantigripaladyuvadaenpoblacionde65omasanosdeedad
AT bouzajosemariaeiros eficaciaefectividadyseguridaddelavacunaantigripaladyuvadaenpoblacionde65omasanosdeedad
AT rubiopereplans eficaciaefectividadyseguridaddelavacunaantigripaladyuvadaenpoblacionde65omasanosdeedad
AT puigbarberajoan eficaciaefectividadyseguridaddelavacunaantigripaladyuvadaenpoblacionde65omasanosdeedad
AT aragonjesusruiz eficaciaefectividadyseguridaddelavacunaantigripaladyuvadaenpoblacionde65omasanosdeedad
AT lanaalvarotorres eficaciaefectividadyseguridaddelavacunaantigripaladyuvadaenpoblacionde65omasanosdeedad